Illumina lodges appeal against EU regulator's Grail deal interim measures
US gene-sequencer Illumina lodged an appeal at the EU courts on Wednesday contesting the European Commission’s imposition of interim measures related to its acquisition of cancer-testing company Grail, MLex has learned.Illumina lodged...To view the full article, register now.
Already a subscriber? Click here to view full article